FIBROGEN WKN: A12EZ0 ISIN: US31572Q8087 Kürzel: 1FG Forum: Aktien Thema: Hauptdiskussion

👀☕

Diese Entscheidung solltest du für dich treffen.

Verkaufen ?

FibroGen's drug fails late-stage trial for treating lung disease https://www.reuters.com/business/healthcare-pharmaceuticals/fibrogens-lung-disease-treatment-fails-late-stage-trial-2023-06-26/

https://www.globenewswire.com/news-release/2023/06/26/2694309/0/en/FibroGen-Announces-Topline-Results-from-Phase-3-ZEPHYRUS-1-Study-of-Pamrevlumab-for-the-Treatment-of-Idiopathic-Pulmonary-Fibrosis.html

https://www.reuters.com/business/healthcare-pharmaceuticals/fibrogens-neuromuscular-disorder-drug-fails-late-stage-study-2023-06-07/ FibroGen's neuromuscular disorder drug fails in late-stage study

FibroGen Announces Positive Topline Results from China Pivotal Phase 3 Clinical Trial of Roxadustat for the Treatment of Chemotherapy Induced Anemia https://investor.fibrogen.com/news-releases/news-release-details/fibrogen-announces-positive-topline-results-china-pivotal-phase • Met primary endpoint of noninferiority of roxadustat to erythropoietin alfa • Plan to file supplemental New Drug Application in China

FibroGen Enters into Exclusive License for FOR46 with Fortis Therapeutics https://www.globenewswire.com/news-release/2023/05/08/2663795/33525/en/FibroGen-Enters-into-Exclusive-License-for-FOR46-with-Fortis-Therapeutics.html

FibroGen Reports First Quarter 2023 Financial Results https://finance.yahoo.com/news/fibrogen-reports-first-quarter-2023-200100063.html

https://beststocks.com/fibrogen-secures-nondilutive-term-loan-financ/

https://seekingalpha.com/news/3941377-fibrogen-gaap-eps-of-0_70-beats-0_25-revenue-of-34_37m-beats-10_42m FibroGen GAAP EPS of -$0.70 beats by $0.25, revenue of $34.37M beats by $10.42M

FibroGen Reports Fourth Quarter and Full Year 2022 Financial Results https://www.globenewswire.com/news-release/2023/02/27/2616460/33525/en/FibroGen-Reports-Fourth-Quarter-and-Full-Year-2022-Financial-Results.html • Topline Data from Five Pivotal Phase 3 Trials in 2023 • Total Company Revenue $140.7 Million in 2022 • Continued Strong Roxadustat Volume Growth in China

William Blair Upgrades FibroGen to Outperform https://www.benzinga.com/news/23/01/30636166/william-blair-upgrades-fibrogen-to-outperform

FibroGen boosted to outperform at Raymond James on idiopathic pulmonary fibrosis candidate https://seekingalpha.com/news/3928500-fibrogen-boosted-to-outperform-at-raymond-james-on-idiopathic-pulmonary-fibrosis-candidate • Raymond James has upgraded FibroGen to outperform from market perform as it sees bullish prospects for phase 3 idiopathic pulmonary fibrosis (IPF) candidate pamrevlumab. • The firm has a $35 price target (69% upside based on Wednesday's close). ... • Analyst Danielle Brill is optimistic on phase 3 data for pamrevlumab given de-risking provided by phase 2 data. The mid-stage trial lasted for 48 weeks. • She added that given current treatments for IPF don't do much to halt disease progression and are marred by tolerability issues, pamrevlumab, which is given every three weeks via injection, will have a role based on discussions with key opinion leaders. • Brill noted that if the phase 3 trial is successful -- similar efficacy to standard of care but with a better safety profile -- the stock could break $50.